The regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor and ruzasvir (RZR), an NS5A inhibitor, is advancing in a global Phase 3 development program for the treatment of hepatitis C virus (HCV). In July 2026, Atea announced that C-BEYOND, its Phase 3 trial conducted in North America evaluating the regimen of BEM/RZR compared to the regimen of sofosbuvir and velpatasvir (SOF/VEL; Epclusa®) achieved its primary and secondary endpoints.
Atea is late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases.
Hepatitis C (HCV) and Hepatitis E (HEV)
Hepatitis C (HCV) and Hepatitis E (HEV)
Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV).
Updates on the regimen of bemnifosbuvir / ruzasvir for the treatment of HCV, AT-587 for the treatment of HEV and other Atea news.
Atea is late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases.
Copyright © 2025 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use